EP300 and B-cell non-Hodgkin lymphoma: While UTX mutations are rare in GC B-cell lymphomas [25], a high incidence of inactivating mutations in the components of COMPASS and its partner HATs, including KMT2D, CREBBP, and EP300, has been reported [26, 27].